An interventional study of Laser Pen and Observation in Headache, Migraine, sponsored by Taichung Veterans General Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Taichung Veterans General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Migraine Disorders with a site in Taiwan — 9 open to participants now, 13 under way, 2 of them phase 3. Migraine Disorders · Taiwan.
Among the 28 studies in Migraine Disorders with a site in Taiwan, this one is the 20th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 24th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →9 of the 28 studies in Migraine Disorders with a site in Taiwan are open now. Recruiting first, the newest first:
Taichung Veterans General Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
Tsai, Chueh-Yi, MD · Sites in Taiwan
Ages 18–70
Changhua Christian Hospital · Sites in Taiwan
Ages 18–65
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18+ · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 140 across the 25 interventional studies, 200 across the 3 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 28 have an industry lead sponsor. The 10 most frequent:
Taichung Veterans General Hospital is the lead sponsor of 176 studies on the registry; 39 are open to participants now.
Taichung Veterans General Hospital has 3 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Migraine Disorders with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496034Phase 3Tsai, Chueh-Yi, MDEfficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine | 2026-12-31 |
| NCT06398353Chang Gung Memorial HospitalInvestigating the Impact of Acupuncture on the Quality of Life of Primitive Headaches Patients | 2027-06-01 |
| NCT06584409Taichung Veterans General HospitalMigraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Migraine Disorders with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aims:
To investigate the efficacy of laser-acupuncture for the severity of primary headache and comorbidities, and the Lab data examination.
Methods:
In this hospital-based prospective single blind randomized sham-controlled study, patients over 18 years old with primary headache will be randomly divided into two treatment arms including laser-acupuncture and sham-controlled group. The expected laser-acupuncture protocol will be bilateral BL2, GB20, EX-HN5, GB8, LI4, LR3 and midline EX-HN3 in totally eight sessions at the first month. In the sham-laser-acupuncture group, patients will receive eight sessions of laser-acupuncture for free after unblinding. We expected to track patients for at least half year. The diagnosis and classification of headache was evaluated using the ICHD-3 criteria. The severity of headache was evaluated using Migraine Disability Assessment (MIDAS) and headache diary provided by Taiwan Headache Society. The co-primary efficacy end points are change in migraine days per month and variation of MIDAS. The secondary end point is the reducing of the severity of comorbidities including headache related anxiety and depression, and both of the quality of life and sleep.
In addition, patients' characteristics will be investigated as follows:
Importance:
In our hospital, we perform laser-acupuncture for patients with headache for several years. A prospective randomized controlled study is the key tools to establish the efficacy of laser-acupuncture for primary headache, and the Lab data with MMP2, CGRP, substance P, beta-endorphin for approval. Look forward to help improve therapeutic strategies in clinical practice.
Headache is one of the most common complaints encountered in medical institution as known as an almost universal human experience. Approximately 65% of headaches are classified as primary, which was a composite of migraine, tension-type headache, trigeminal autonomic cephalalgia and other primary headaches according to the third edition of the International Classification of Headache Disorders (ICHD-3). Primary headaches encompass a heterogeneous group of neurologic disorders and might be bothersome for patients.
It's well established that acupuncture can be considered a treatment option for migraine prevention. The efficacy of laser-acupuncture is similar to acupuncture, and laser-acupuncture is a non-invasive therapeutic approach and safety. It could reduce the risk of hemorrhage, infection and needle phobia. However, the efficacy of laser-acupuncture in primary headache remains inconclusive.
MMP2, CGRP, substance P, beta-endorphin are new Lab examination for following up the patients suffered from migraine.
Aims:
To investigate the efficacy of laser-acupuncture for the severity of primary headache and comorbidities, and the Lab data examination.
Methods:
In this hospital-based prospective single blind randomized sham-controlled study, patients over 18 years old with primary headache will be randomly divided into two treatment arms including laser-acupuncture and sham-controlled group. The expected laser-acupuncture protocol will be bilateral BL2, GB20, EX-HN5, GB8, LI4, LR3 and midline EX-HN3 in totally eight sessions at the first month. In the sham-laser-acupuncture group, patients will receive eight sessions of laser-acupuncture for free after unblinding. We expected to track patients for at least half year. The diagnosis and classification of headache was evaluated using the ICHD-3 criteria. The severity of headache was evaluated using Migraine Disability Assessment (MIDAS) and headache diary provided by Taiwan Headache Society. The co-primary efficacy end points are change in migraine days per month and variation of MIDAS. The secondary end point is the reducing of the severity of comorbidities including headache related anxiety and depression, and both of the quality of life and sleep.
In addition, patients' characteristics will be investigated as follows:
Importance:
In our hospital, we perform laser-acupuncture for patients with headache for several years. A prospective randomized controlled study is the key tools to establish the efficacy of laser-acupuncture for primary headache, and the Lab data with MMP2, CGRP, substance P, beta-endorphin for approval. Look forward to help improve therapeutic strategies in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CM patients with unsatisfactory pharmacological effects receive laser acupuncture for 8 sessions that spanned 4 weeks. Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
Device: Laser Pen
CM patients with unsatisfactory pharmacological effects receive sham treatment for 8 sessions that spanned 4 weeks. Sham treatment had no laser output.
Other: Observation
Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3) After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months.
cGRP
change in cGRP from baasline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
MMP2
change in MMP2 from baasline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
Difference in the number of headache days per month
change in monthly migraine days (MMD) from baseline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
Difference in the of headache attacks lasting hours per month
change in acute headache medications usage days per month from baseline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
Difference in the headache pain intensity (NRS)
changes in the headache severity (based on NRS) between baseline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
Difference in the number of days with acute headache medication intake per month
change in acute headache medications usage days per month from baseline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
Difference in the Migraine Disability Assessment
changes in the Migraine Disability Assessmen between baseline and each follow-up time point. Title: Migraine Disability Assessmen Maximum value:450 Minimum value:0 Higher scores mean: worsen outcome
Time frame: 12 weeks, 24 weeks, 36 weeks
Difference in the Beck's Depression Inventory
change in Beck's Depression Inventory between baseline and each follow-up time point Title:Beck's Depression Inventory Maximum value:63 Minimum value:0 Higher scores mean: worsen outcome
Time frame: 12 weeks, 24 weeks, 36 weeks
Difference in the Hospital Anxiety and Depression Scale
change in Hospital Anxiety and Depression Scale between baseline and each follow-up time point Title:Hospital Anxiety and Depression Scale Maximum value:21/21 Minimum value:0/0 Higher scores mean:worsen outcome
Time frame: 12 weeks, 24 weeks, 36 weeks
30% reduction in migraine days
≥ 30% reduction in migraine days between baseline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
Substance P
change in Substance P from baasline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
beta-endorphin
change in beta-endorphin from baasline and each follow-up time point
Time frame: 12 weeks, 24 weeks, 36 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 30 months after the start.
Of 309 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 30 months is above that.
Counting every sponsor, half of 358 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2025 → Nov 2027, on Sep 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taichung Veterans General Hospital →